Just how helpful is personalized genomic analysis anyway?

Regular readers of the medical science literature will be very conscious of the emphasis on genomic analysis of tumor specimens as a way to try to “personalize” treatment of cancers of many types — prostate cancer very specifically included. … READ MORE …

Race, obesity, and risk for prostate cancer

By using data from the prospective SELECT trial (the Selenium and Vitamin E Cancer Prevention Trial, conducted between 2001 and 2011), researchers have been able to suggest that obesity is strongly associated with increased risk for prostate cancer diagnosis among African American males compared to non-Hispanic whites. … READ MORE …

“Psychosocial interventions in prostate cancer offer limited benefits”

The heading above is the title of a Reuters-generated article on the Medcape Oncology web site. The article is based on a new review article just published in BJU International. … READ MORE …

Slow but increasing uptake of observation in initial management of low-risk patients

A new article by Maurice et al. in the Canadian Urological Association Journal provides detailed information about the use of initial observation as a management strategy for low-risk prostate cancer between 2004 and 2011. … READ MORE …

Are prostate cancer-specific mortality rates in Australia higher than they should be?

An article just published in the World Journal of Urology has suggested that rates of prostate cancer-specific mortality in Australia seem to have been unexpectedly higher than in the USA. … READ MORE …

The side effects of radical prostatectomy: a new review

A new review article by a Danish research team in the Journal of Sexual Medicine has (arguably) brought a degree of clarity to what the authors refer to as “neglected” side effects consequent to radical prostatectomy. Unfortunately the average urologist probably doesn’t read the Journal of Sexual Medicine on a regular basis. … READ MORE …

New data on 5-ARI treatment in prevention of and and risk for prostate cancer

A new article in the journal JAMA Oncology has again suggested that the use of 5α-reductase inhibitors (5-ARIs) like finasteride/Proscar and dutasteride/Avodart is not, in fact, associated with any significant risk for clinically significant prostate cancer let alone risk for prostate cancer-specific mortality. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,258 other followers